DNB Markets recommends to sell Genmab stock
Genmab’s share price target has been lowered from DKK 2,982 to DKK 2,705 (USD 431.2 to USD 391.1) by Norwegian investment bank DNB Markets, which assesses that the biotech company’s 2023 prognosis will disappoint.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Three Genmab cancer drugs close in on big milestones in 2023
For subscribers
Genmab and Abbvie file for cancer drug approval in Japan
For subscribers
Genmab gets new MS market rival after fresh FDA approval
For subscribers